Table 1.
Characteristics of the 120 patients at the time of diagnosis of gemcitabine‐associated thrombotic microangiopathy
| Patients (n = 120) | |||
|---|---|---|---|
| Age | 61.5 (54–68.25) | ||
| Sex, male (%) | 68 (56.7%) | ||
| Medical background (n = 88) | |||
| Cardiovascular disease | 10.2% | ||
| Hypertension | 31.8% | ||
| Diabetes | 11.3% | ||
| Dyslipidaemia | 11.3% | ||
| COPD | 7.9% | ||
| Tobacco use | 15.9% | ||
| Alcoholism | 7.9% | ||
| CKD | 7.9% | ||
| Other cancer | 9.1% | ||
| Autoimmune disease | 4.5% | ||
| Type of cancer treated with gemcitabine (n = 119) | |||
| Pancreas | 52.9% | ||
| Lung | 12.6% | ||
| Breast | 7.6% | ||
| Cholangiocarcinoma and biliary tract cancers | 6.7% | ||
| Bladder | 4.2% | ||
| Ovarian cancer | 3.4% | ||
| Mesothelioma | pleural | 2.5% | |
| peritoneal | 0.8% | ||
| Lymphoma | Non‐Hodgkin | 2.5% | |
| Hodgkin | 2.5% | ||
| Uterus | 1.7% | ||
| Mycosis fungoid | 0.8% | ||
| Testicle | 0.8% | ||
| Liver | 0.8% | ||
| Metastatic cancer | 34.2% | ||
| Chemotherapy prior to gemcitabine (n = 104) | 45.2% | ||
| Concomitant treatments | |||
| Chemotherapy (n = 80) | 41.2% | ||
| Hormonotherapy (n = 80) | 2.5% | ||
| Anticoagulants or antiaggregants (n = 79) | 19% | ||
| clopidrogel, ticlodipin | 2.5% | ||
Age is expressed as median with interquartile ranges. All qualitative variables are expressed as percentages calculated among patients for whom the information was available, therefore excluding the missing data. COPD, chronic obstructive pulmonary disease, CKD: chronic kidney disease